Statin Exposure and Risk of Colorectal Cancer in Patients with Inflammatory Bowel Disease: a Systematic Review and Meta-analysis

Overview

Journal Front Med (Lausanne)

Specialty General Medicine

Date 2024 Dec 9

PMID 39650188

Authors

Ai-Juan Li

Hai-Yin Jiang

Yong-Hui Jia

Affiliations

Soon will be listed here.

Abstract

Background: While epidemiological studies have linked statin use to a reduced risk of advanced colorectal adenomas, its impact on colorectal cancer (CRC) risk in patients with inflammatory bowel disease (IBD) remains unclear. To our knowledge, no meta-analysis to date has specifically examined this association. Therefore, we conducted a systematic review and meta-analysis of the available observational studies to investigate the risk of CRC associated with statin use in IBD patients.

Methods: We searched three databases for articles published in English before September 2024, focusing on the protective effects of statins against CRC in IBD patients. We calculated multivariate odds ratios (ORs) and their 95% confidence intervals (CIs) to assess this association. A random-effects meta-analysis was conducted using the generic inverse variance method.

Results: The meta-analysis included 4 studies encompassing 22,250 IBD patients, 6,712 of whom were statin users. The methodological quality of three of the studies was deemed high. We found a significantly lower risk of CRC in statin users compared to non-users, with a pooled relative risk of 1.88 (95% CI 1.54-2.30). Sensitivity analyses confirmed the consistency of these findings.

Conclusion: Statin use appears to be associated with a reduced risk of CRC in patients with IBD. However, given the limited number of studies available, further prospective research with large sample size is necessary to confirm the potential chemopreventive role of statins in this population.

References

Ji L, Liu C, Yuan Y, Gao H, Tang Z, Yang Z . Key roles of Rho GTPases, YAP, and Mutant P53 in anti-neoplastic effects of statins. Fundam Clin Pharmacol. 2019; 34(1):4-10. DOI: 10.1111/fcp.12495. View

Lytras T, Nikolopoulos G, Bonovas S . Statins and the risk of colorectal cancer: an updated systematic review and meta-analysis of 40 studies. World J Gastroenterol. 2014; 20(7):1858-70. PMC: 3930985. DOI: 10.3748/wjg.v20.i7.1858. View

Jeong G, Lee K, Kim J, Eisenhut M, Kronbichler A, van der Vliet H . Effect of Statin on Cancer Incidence: An Umbrella Systematic Review and Meta-Analysis. J Clin Med. 2019; 8(6). PMC: 6617015. DOI: 10.3390/jcm8060819. View

Liu Y, Tang W, Wang J, Xie L, Li T, He Y . Association between statin use and colorectal cancer risk: a meta-analysis of 42 studies. Cancer Causes Control. 2013; 25(2):237-49. DOI: 10.1007/s10552-013-0326-6. View

Argollo M, Gilardi D, Peyrin-Biroulet C, Chabot J, Peyrin-Biroulet L, Danese S . Comorbidities in inflammatory bowel disease: a call for action. Lancet Gastroenterol Hepatol. 2019; 4(8):643-654. DOI: 10.1016/S2468-1253(19)30173-6. View

Bedi O, Dhawan V, Sharma P, Kumar P . Pleiotropic effects of statins: new therapeutic targets in drug design. Naunyn Schmiedebergs Arch Pharmacol. 2016; 389(7):695-712. DOI: 10.1007/s00210-016-1252-4. View

Baumgart D, Sandborn W . Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007; 369(9573):1641-57. DOI: 10.1016/S0140-6736(07)60751-X. View

Bryniarski K, den Dekker W, Legutko J, Gasior P, Tahon J, Diletti R . Role of Lipid-Lowering and Anti-Inflammatory Therapies on Plaque Stabilization. J Clin Med. 2024; 13(11). PMC: 11172633. DOI: 10.3390/jcm13113096. View

Lau J, Ioannidis J, Terrin N, Schmid C, Olkin I . The case of the misleading funnel plot. BMJ. 2006; 333(7568):597-600. PMC: 1570006. DOI: 10.1136/bmj.333.7568.597. View

10.

Kosumi K, Hamada T, Koh H, Borowsky J, Bullman S, Twombly T . The Amount of Bifidobacterium Genus in Colorectal Carcinoma Tissue in Relation to Tumor Characteristics and Clinical Outcome. Am J Pathol. 2018; 188(12):2839-2852. PMC: 6284552. DOI: 10.1016/j.ajpath.2018.08.015. View

11.

Samadder N, Mukherjee B, Huang S, Ahn J, Rennert H, Greenson J . Risk of colorectal cancer in self-reported inflammatory bowel disease and modification of risk by statin and NSAID use. Cancer. 2011; 117(8):1640-8. PMC: 3117060. DOI: 10.1002/cncr.25731. View

12.

Higgins J, Thompson S, Deeks J, Altman D . Measuring inconsistency in meta-analyses. BMJ. 2003; 327(7414):557-60. PMC: 192859. DOI: 10.1136/bmj.327.7414.557. View

13.

Lutgens M, van Oijen M, van der Heijden G, Vleggaar F, Siersema P, Oldenburg B . Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. Inflamm Bowel Dis. 2013; 19(4):789-99. DOI: 10.1097/MIB.0b013e31828029c0. View

14.

Fatakhova K, Rajapakse R . From random to precise: updated colon cancer screening and surveillance for inflammatory bowel disease. Transl Gastroenterol Hepatol. 2024; 9:27. PMC: 11074484. DOI: 10.21037/tgh-23-36. View

15.

Demierre M, Higgins P, Gruber S, Hawk E, Lippman S . Statins and cancer prevention. Nat Rev Cancer. 2005; 5(12):930-42. DOI: 10.1038/nrc1751. View

16.

Brandaleone L, Dal Buono A, Gabbiadini R, Marcozzi G, Polverini D, Carvello M . Hereditary Colorectal Cancer Syndromes and Inflammatory Bowel Diseases: Risk Management and Surveillance Strategies. Cancers (Basel). 2024; 16(17). PMC: 11394661. DOI: 10.3390/cancers16172967. View

17.

Ananthakrishnan A, Cagan A, Cai T, Gainer V, Shaw S, Churchill S . Statin Use Is Associated With Reduced Risk of Colorectal Cancer in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2016; 14(7):973-9. PMC: 4912917. DOI: 10.1016/j.cgh.2016.02.017. View

18.

Shah S, Glass J, Giustino G, Ten Hove J, Castaneda D, Torres J . Statin Exposure Is Not Associated with Reduced Prevalence of Colorectal Neoplasia in Patients with Inflammatory Bowel Disease. Gut Liver. 2018; 13(1):54-61. PMC: 6346999. DOI: 10.5009/gnl18178. View

19.

She J, Sun L, Yu Y, Fan H, Li X, Zhang X . A gut feeling of statin. Gut Microbes. 2024; 16(1):2415487. PMC: 11540068. DOI: 10.1080/19490976.2024.2415487. View

20.

Wong W, Dimitroulakos J, Minden M, Penn L . HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia. 2002; 16(4):508-19. DOI: 10.1038/sj.leu.2402476. View